{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:34:04Z","timestamp":1793259244795,"version":"4.5.0"},"reference-count":43,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13298","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:22:38Z","timestamp":1789363358000},"page":"1-12","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor\u2011induced myocarditis with myositis and\/or myasthenia gravis overlap syndrome: A case series"],"prefix":"10.3892","volume":"32","author":[{"given":"Qing","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Neurology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Surgical Intensive Care Unit, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dantao","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Neurology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renbin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"key20261029091434_b1-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/RHU.0000000000001874","article-title":"Immune checkpoint inhibitor-associated myositis: A distinct form of inflammatory myopathy","volume":"28","author":"Saygin","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"key20261029091434_b2-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1097\/RHU.0000000000001209","article-title":"Checkpoint inhibitor-associated autoimmunity: What a rheumatologist needs to know","volume":"28","author":"Ghosh","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"key20261029091434_b3-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"key20261029091434_b4-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20261029091434_b5-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"key20261029091434_b6-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: A systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"key20261029091434_b7-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/cam4.5050","article-title":"Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single-center case series","volume":"12","author":"Longinow","year":"2023","journal-title":"Cancer Med"},{"key":"key20261029091434_b8-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajem.2021.03.005","article-title":"Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome","volume":"46","author":"Lipe","year":"2021","journal-title":"Am J Emerg Med"},{"key":"key20261029091434_b9-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2217\/imt-2021-0225","article-title":"Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: A case series and review","volume":"14","author":"Wai Siu","year":"2022","journal-title":"Immunotherapy"},{"issue":"714460","key":"key20261029091434_b10-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.714460","article-title":"Case report: The neuromusclar triad of immune checkpoint inhibitors: A case report of myositis, myocarditis, and myasthenia gravis overlap following toripalimab treatment","volume":"8","author":"Luo","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"250","key":"key20261029091434_b11-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma","volume":"8","author":"Xing","year":"2020","journal-title":"Ann Transl Med"},{"issue":"5126717","key":"key20261029091434_b12-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5126717","article-title":"The terrible triad of checkpoint inhibition: A case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Reports Immunol"},{"issue":"950801","key":"key20261029091434_b13-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.950801","article-title":"Myocarditis and myositis\/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature","volume":"9","author":"Yin","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"310","key":"key20261029091434_b14-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-023-02257-z","article-title":"Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: A case series and review of the literature","volume":"23","author":"Cuenca","year":"2023","journal-title":"BMC Anesthesiol"},{"key":"key20261029091434_b15-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: An international cardio-oncology society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"e002890","key":"key20261029091434_b16-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key20261029091434_b17-ETM-32-5-13298"},{"key":"key20261029091434_b18-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"key20261029091434_b19-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/mus.26381","article-title":"Needle electromyography and histopathologic correlation in myopathies","volume":"59","author":"Sener","year":"2019","journal-title":"Muscle Nerve"},{"issue":"e013757","key":"key20261029091434_b20-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: Pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"key20261029091434_b21-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"key20261029091434_b22-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/ehf2.14360","article-title":"Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: Rechallenge?","volume":"10","author":"Rossi","year":"2023","journal-title":"ESC Heart Fail"},{"key":"key20261029091434_b23-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1161\/CIRCULATIONAHA.123.066565","article-title":"Half-life and clearance of cardiac troponin I and troponin T in humans","volume":"150","author":"Kristensen","year":"2024","journal-title":"Circulation"},{"key":"key20261029091434_b24-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1373\/clinchem.2011.175059","article-title":"Concordance, variance, and outliers in 4 contemporary cardiac troponin assays: Implications for harmonization","volume":"58","author":"Ungerer","year":"2012","journal-title":"Clin Chem"},{"key":"key20261029091434_b25-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.jacc.2018.01.070","article-title":"Elevated cardiac troponin T in patients with skeletal myopathies","volume":"71","author":"Schmid","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"key20261029091434_b26-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3899\/jrheum.090562","article-title":"Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies","volume":"36","author":"Aggarwal","year":"2009","journal-title":"J Rheumatol"},{"key":"key20261029091434_b27-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"key":"key20261029091434_b28-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"issue":"2063","key":"key20261029091434_b29-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: A narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20261029091434_b30-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20261029091434_b31-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"key20261029091434_b32-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: Illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist"},{"issue":"518","key":"key20261029091434_b33-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07987-x","article-title":"Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: A case series","volume":"31","author":"Weaver","year":"2023","journal-title":"Support Care Cancer"},{"issue":"5611","key":"key20261029091434_b34-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195611","article-title":"Immune checkpoint inhibitor-induced myositis\/myocarditis with myasthenia gravis-like misleading presentation: A case series in intensive care unit","volume":"11","author":"Deharo","year":"2022","journal-title":"J Clin Med"},{"key":"key20261029091434_b35-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/1750743X.2025.2517522","article-title":"Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: Case report","volume":"17","author":"Cobelas-Cartagena","year":"2025","journal-title":"Immunotherapy"},{"issue":"1769065","key":"key20261029091434_b36-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1769065","article-title":"Case report: Efgartigimod combined with intravenous methylprednisolone in a case of co-occurrence of unexplained myasthenia gravis, inflammatory myopathy, and fulminant myocarditis","volume":"17","author":"Yang","year":"2026","journal-title":"Front Immunol"},{"key":"key20261029091434_b37-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1007\/s10072-024-07972-0","article-title":"Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: A case report","volume":"46","author":"Rigamonti","year":"2025","journal-title":"Neurol Sci"},{"issue":"17562864251333518","key":"key20261029091434_b38-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251333518","article-title":"Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: A case report","volume":"18","author":"Huang","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"issue":"e16229","key":"key20261029091434_b39-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur J Neurol"},{"issue":"225","key":"key20261029091434_b40-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-025-04681-0","article-title":"Pyridostigmine-induced complete atrioventricular block in a patient with Musk antibody-negative myasthenia gravis a case report: Pyridostigmine-ind advanced AV block in MG patient with MuSK-neg","volume":"25","author":"Godarzi","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"key20261029091434_b41-ETM-32-5-13298","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-induced arrhythmias: A scientific statement from the american heart association","volume":"142","author":"Tisdale","year":"2020","journal-title":"Circulation"},{"issue":"e13396","key":"key20261029091434_b42-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13396","article-title":"The effects of acetylcholinesterase inhibitors on the heart in acute myocardial infarction and heart failure: From cells to patient reports","volume":"228","author":"Khuanjing","year":"2020","journal-title":"Acta Physiol (Oxf)"},{"issue":"1243","key":"key20261029091434_b43-ETM-32-5-13298","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13071243","article-title":"Immune checkpoint inhibitors-related myocarditis: A review of reported clinical cases","volume":"13","author":"Zotova","year":"2023","journal-title":"Diagnostics (Basel)"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:14:39Z","timestamp":1793258079000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,14]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13298","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}